LGALS3 and non-Hodgkin lymphoma: To clarify the potential pro- or antitumor properties of galectin-3 in NHL, we next determined the effect of galectin-3 deficiency in the λ-MYC model of aggressive B-cell lymphoma.6 As shown in Figure 6a, galectin-3-deficient mice developed tumors less frequently compared with their WT counterparts.